July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Nathan A. Pennell: Pralsetinib development outside the US and China also stopped
Jan 13, 2024, 10:04

Nathan A. Pennell: Pralsetinib development outside the US and China also stopped

Nathan A. Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program, shared a post by EGFR Resisters on X/Twitter:

“Oh man, pralsetinib (for RET+ tumors) development outside the US and China also stopped. Hope this gets resumed with new partners.”

Quoting EGFR Resisters’s post:

Blueprint Medicines issued press release: “Discontinue further investment in the early clinical stage therapies BLU 945 and 451 for EGFR Non-Small Cell Lung Cancer and explore strategic options including potential outlicensing” Blu-945 and Blu-451 clinical trials will close.”

Read further.

Source: Nathan A. Pennell/X and EGFR Resisters/X